Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

NFA_DYOR Sep. 12 at 9:55 AM

$GRI Dilute yo $0.1 Do a 1:100 RS and price will be $10 Hehe

0 · Reply

ka1954 Sep. 11 at 6:00 PM

$GRI fuckinig wainwright have had $10 PT since 2 reverse splits ago. these idiots don't know a good stock if it hit them in their fucking face

0 · Reply

Elmaestro11 Sep. 11 at 5:35 PM

$GRI Who grabbed some under $2 ? 🤑

0 · Reply

brallt Sep. 11 at 2:47 PM

$GRI soon to be 2+. 👀

0 · Reply

0xtechnerd Sep. 11 at 2:42 PM

$GRI

0 · Reply

Amscru80 Sep. 11 at 2:27 PM

$SLS $GRI 💎💎

0 · Reply

Elmaestro11 Sep. 11 at 12:47 PM

$GRI 🤑

0 · Reply

Earth4thewin Sep. 11 at 12:33 AM

$GRI how many times can the float turn over before this thing absolutely explodes to the upside ?

0 · Reply

Elmaestro11 Sep. 10 at 4:27 PM

$GRI Soon imo. 🤑🐂

0 · Reply

HOCKEYPUCK1972 Sep. 10 at 3:54 PM

$GRI

0 · Reply

GRI Bio announces new translational biomarker data from GRI-0621-IPF-02 study

Sep 8, 2026, 8:15 AM EDT - 4 days ago

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

Aug 27, 2026, 9:01 AM EDT - 16 days ago

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Aug 24, 2026, 9:05 AM EDT - 19 days ago

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

Aug 20, 2026, 12:23 PM EDT - 23 days ago

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

AGG ARBK BIL BITQ BLOK BND BNDX

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

GRI Bio Quarterly report: Q2 2026

2026-06-18T13:05:38.000Z - 2 months ago

GRI Bio announces U.S. FDA granted ODD to GRI-0621

Jun 18, 2026, 8:31 AM EDT - 2 months ago

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

2026-06-17T15:00:10.000Z - 2 months ago

GRI Bio granted FDA orphan designation for tazarotene

May 18, 2026, 9:15 AM EDT - 3 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2026, 8:35 AM EDT - 4 months ago

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

May 13, 2026, 7:00 AM EDT - 4 months ago

GRI Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

GRI Bio Earnings release: Q1 2026

2026-04-08T13:21:10.000Z - 5 months ago

GRI Bio receives UAE patent allowance for inflammatory disease treatments

Apr 8, 2026, 8:30 AM EDT - 5 months ago

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Mar 6, 2026, 6:00 AM EST - 6 months ago

GRI Bio Slides: Corporate presentation

Feb 17, 2026, 9:15 AM EST - 6 months ago

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Feb 11, 2026, 1:00 PM EST - 7 months ago

GRI Bio Transcript: Corporate Connect Webinar Series

Feb 5, 2026, 9:15 AM EST - 7 months ago

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

2026-02-04T13:50:33.000Z - 7 months ago

GRI Bio sees cash runway into 1Q27

Feb 4, 2026, 8:45 AM EST - 7 months ago

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Feb 4, 2026, 8:30 AM EST - 7 months ago

GRI Bio Earnings release: Q4 2025

Feb 4, 2026, 8:30 AM EST - 7 months ago

GRI Bio Annual report: Q4 2025

Jan 30, 2026, 7:00 AM EST - 7 months ago

GRI Bio Registration statement: Registration Filing

2026-01-30T11:11:17.000Z - 7 months ago

GRI Bio files $250M mixed securities shelf

2026-01-28T14:41:21.000Z - 7 months ago

GRI Bio Inc trading resumes

2026-01-28T14:35:28.000Z - 7 months ago

GRI Bio Inc trading halted, volatility trading pause

2026-01-28T13:56:26.000Z - 7 months ago

GRI Bio delivers additional data from Phase 2a study of GRI-0621

Jan 28, 2026, 8:45 AM EST - 7 months ago

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

2026-01-26T13:35:51.000Z - 7 months ago

GRI Bio secures U.S. composition of matter patent

2026-01-24T00:50:50.000Z - 7 months ago

GRI Bio Inc trading halted, news pending

2026-01-21T21:25:40.000Z - 7 months ago

GRI Bio announces 1-for-28 reverse stock split

Jan 21, 2026, 4:01 PM EST - 7 months ago

GRI Bio Announces Reverse Stock Split

Jan 15, 2026, 9:00 AM EST - 8 months ago

GRI Bio Transcript: EGM 2026

2026-01-08T13:39:21.000Z - 8 months ago

GRI Bio announces data from Phase 2a study in Idiopathic Pulmonary Fibrosis

Dec 29, 2025, 7:00 AM EST - 8 months ago

GRI Bio Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

GRI Bio Proxy statement: Proxy Filing

Dec 12, 2025, 4:05 PM EST - 9 months ago

GRI Bio Announces Closing of $8.0 Million Public Offering

2025-12-11T14:20:13.000Z - 9 months ago

GRI Bio prices 10.67M shares at 75c in public offering

Dec 11, 2025, 9:15 AM EST - 9 months ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

2025-12-10T21:41:18.000Z - 9 months ago

GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints

Dec 10, 2025, 4:05 PM EST - 9 months ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Dec 10, 2025, 7:00 AM EST - 9 months ago

GRI Bio Registration statement: Registration Filing

2025-12-08T13:25:31.000Z - 9 months ago

GRI Bio files to sell 5.13M shares of common stock, warrants

Dec 8, 2025, 7:00 AM EST - 9 months ago

GRI Bio Registration statement: Registration Filing

Nov 14, 2025, 7:00 AM EST - 10 months ago

GRI Bio Quarterly report: Q3 2025

2025-09-11T12:50:15.000Z - 1 year ago

GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621

Sep 11, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 9, 2025, 3:00 PM EDT - 1 year ago

GRI Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:00 PM EDT - 1 year ago

GRI Bio Quarterly report: Q2 2025

Aug 14, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 1 year ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

2025-07-31T13:05:39.000Z - 1 year ago

GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF

Jul 22, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 11, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Jul 6, 2025, 6:00 PM EDT - 1 year ago

GRI Bio Slides: Corporate Presentation

2025-07-01T12:50:17.000Z - 1 year ago

GRI Bio completes enrollment in Phase 2a study of GRI-0621

Jul 1, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 1 year ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: Alliance Global Partners Healthcare Company Showcase

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 15, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

GRI Bio Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

GRI Bio Earnings release: Q1 2025

May 8, 2025, 8:45 AM EDT - 1 year ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 1 year ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 1 year ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Mar 31, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 26, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Registration statement: Registration Filing

Mar 25, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Registration statement: Registration Filing

Mar 18, 2025, 9:05 AM EDT - 1 year ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 1 year ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 14, 2025, 7:30 AM EDT - 1 year ago

GRI Bio Earnings release: Q4 2024

Mar 14, 2025, 7:30 AM EDT - 1 year ago

GRI Bio Annual report: Q4 2024

Mar 11, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Jan 17, 2025, 7:00 AM EST - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Jan 7, 2025, 7:00 AM EST - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 6, 2024, 7:00 AM EST - 1 year ago

GRI Bio Slides: Corporate Presentation

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Registration statement: Registration Filing

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 14, 2024, 8:05 AM EDT - 2 years ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Slides: Q2 2024

Aug 2, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Jul 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Jul 15, 2024, 9:05 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 8th Annual IPF Summit

NFA_DYOR Sep. 12 at 9:55 AM

$GRI Dilute yo $0.1 Do a 1:100 RS and price will be $10 Hehe

0 · Reply

ka1954 Sep. 11 at 6:00 PM

$GRI fuckinig wainwright have had $10 PT since 2 reverse splits ago. these idiots don't know a good stock if it hit them in their fucking face

0 · Reply

Elmaestro11 Sep. 11 at 5:35 PM

$GRI Who grabbed some under $2 ? 🤑

0 · Reply

brallt Sep. 11 at 2:47 PM

$GRI soon to be 2+. 👀

0 · Reply

0xtechnerd Sep. 11 at 2:42 PM

$GRI

0 · Reply

Amscru80 Sep. 11 at 2:27 PM

$SLS $GRI 💎💎

0 · Reply

Elmaestro11 Sep. 11 at 12:47 PM

$GRI 🤑

0 · Reply

Earth4thewin Sep. 11 at 12:33 AM

$GRI how many times can the float turn over before this thing absolutely explodes to the upside ?

0 · Reply

Elmaestro11 Sep. 10 at 4:27 PM

$GRI Soon imo. 🤑🐂

0 · Reply

HOCKEYPUCK1972 Sep. 10 at 3:54 PM

$GRI

0 · Reply

Amscru80 Sep. 10 at 2:53 PM

$SLS $GRI 💎💎

0 · Reply

STACKD0E Sep. 10 at 2:44 PM

$GRI 👁

0 · Reply

brallt Sep. 10 at 2:36 PM

$GRI 2+ coming.

1 · Reply

Earth4thewin Sep. 10 at 1:36 PM

$GRI

0 · Reply

Earth4thewin Sep. 9 at 11:08 PM

$GRI Positive Phase 2a Data (September 2026): At the European Respiratory Society (ERS) Congress, GRI Bio presented late-breaking Phase 2a trial results for GRI-0621. The data demonstrated a +99 mL placebo-adjusted forced vital capacity (FVC) gain overall (and +139 mL on background antifibrotic therapy) at 12 weeks, signaling potential lung function improvement. Advanced RNA sequencing and flow cytometry showed anti-fibrotic, tissue-repair, and immune-rebalancing effects.

0 · Reply

Zardiw Sep. 9 at 10:58 PM

$SUNE +90% since #DDAmanda flagged it. #DDAmanda Chart Similar early alerts: $MTEX $CDTG $GRI Find the next one: https://DDAmanda.com

0 · Reply

NFA_DYOR Sep. 9 at 10:29 PM

$GRI Oh wow I didn't know that phase 2b or 3 is so cheap? Also i didn't know that stocks dilute before runway is over, at least 4-7 months before the runway

0 · Reply

ka1954 Sep. 9 at 10:28 PM

$GRI Idiots like you is why people lose money in stocks. They already have cash to get them through another year

0 · Reply

ka1954 Sep. 9 at 10:27 PM

$GRI all asian stocks are 100 times better than any US junk stocks, especially a few stocks like GRI.

0 · Reply

NFA_DYOR Sep. 9 at 10:03 PM

$GRI Wow All supports are paper thin So it was just pump, dilute, dump, RS

0 · Reply

NFA_DYOR Sep. 9 at 5:13 PM

$GRI What the hell Come back Its being punped and now dumped I guess I'll have to be diluted into

0 · Reply

NFA_DYOR Sep. 9 at 3:49 PM

$GRI What the hell Come back to $2.X i want an exit If they do another big RS say 1:500, ill br doomed

0 · Reply

Market Cap	4.24M
Revenue (ttm)	0.00
Net Income (ttm)	-11.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	131,900
Avg Vol	394,758
Day's Range	N/A - N/A
Shares Out	2.19M
Stochastic %K	9%
Beta	-1.24
Analysts	Sell
Price Target	$18.50